Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||The clinical applications of fluorouracil in ophthalmic practice|
|Citation:||Drugs, 2007; 67(2):237-255|
|Publisher:||Adis International Ltd|
|Lekha M. Abraham, Dinesh Selva, Robert Casson and Igal Leibovitch|
|Abstract:||Fluorouracil (5-fluorouracil, 5-FU) is a pyrimidine analogue that was originally known for its widespread use as an anticancer drug. The ability of 5-FU to reduce fibroblastic proliferation and subsequent scarring has made it an important adjunct in ocular and periorbital surgeries. It is used in primary glaucoma filtering surgeries and in reviving failing filtering blebs, in dacryocystorhinostomy, pterygium surgery, and in vitreoretinal surgery to prevent proliferative vitreoretinopathy. In addition, 5-FU is also gaining recognition in the treatment and surgical management of ocular surface malignancies like ocular surface squamous neoplasia; however, the specific action of the drug on highly proliferating cells limits its use in primary acquired melanosis of the conjunctiva. When applied topically, this drug has a low rate of sight-threatening adverse effects, is inexpensive, and is easy to administer, making it an important tool in enhancing the success rate in ophthalmic surgery and in reducing the recurrence of ocular surface neoplasia.|
|Keywords:||Eye cancer; Eye surgery; Fluorouracil; Mitomycin|
|Description:||Copyright © 2007 Adis Data Information BV. All right reserved.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.